Clinical Trials Directory

Trials / Sponsors / Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Industry · 49 registered clinical trials5 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingA First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Huntington's Disease
Phase 12026-05-05
WithdrawnA Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants
Muscular Dystrophies, Limb-Girdle
Phase 32025-06-30
TerminatedStudy to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb
Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2D/R3
Phase 12025-01-09
TerminatedA Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Followi
Duchenne Muscular Dystrophy
Phase 12024-09-18
Enrolling By InvitationAn Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duche
Duchenne Muscular Dystrophy
2024-02-07
TerminatedA Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) F
Duchenne Muscular Dystrophy
Phase 12024-01-29
Active Not RecruitingA Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a P
Limb-girdle Muscular Dystrophy
Phase 32024-01-15
Enrolling By InvitationA Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous
Duchenne Muscular Dystrophy
Phase 32023-09-27
Active Not RecruitingA Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) i
Duchenne Muscular Dystrophy
Phase 32023-05-31
TerminatedA Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants
Limb Girdle Muscular Dystrophy
Phase 12023-05-22
Active Not RecruitingA Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulat
Limb Girdle Muscular Dystrophy
Phase 12022-12-19
CompletedA Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) i
Duchenne Muscular Dystrophy
Phase 32021-10-27
Active Not RecruitingA Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years o
Limb-girdle Muscular Dystrophy
2021-04-22
RecruitingA Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-
Muscular Dystrophy, Duchenne
Phase 12020-11-23
Active Not RecruitingA Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dyst
Muscular Dystrophy, Duchenne
Phase 32020-07-13
TerminatedTwo-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in P
Duchenne Muscular Dystrophy
Phase 22019-06-26
TerminatedA Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dy
Duchenne Muscular Dystrophy
Phase 22019-06-26
Enrolling By InvitationA Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
Duchenne Muscular Dystrophy
2019-01-07
TerminatedAn Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP
Muscular Dystrophy, Duchenne
Phase 1 / Phase 22018-12-19
CompletedA Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne M
Muscular Dystrophy, Duchenne
Phase 1 / Phase 22018-12-05
TerminatedGene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Musc
Limb-Girdle Muscular Dystrophy, Type 2E
Phase 1 / Phase 22018-10-27
TerminatedAn Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Phase 32018-08-02
CompletedA Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirse
Muscular Dystrophy, Duchenne
Phase 12018-02-05
CompletedA Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participant
Duchenne Muscular Dystrophy
Phase 1 / Phase 22018-01-04
CompletedStudy of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping
Duchenne Muscular Dystrophy
Phase 22017-08-16
CompletedStudy of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD
Duchenne Muscular Dystrophy
Phase 32016-09-28
CompletedrAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
Dysferlinopathy
Phase 12016-03-01
CompletedDose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Phase 12015-10-08
CompletedSafety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD)
Phase 22015-06-30
CompletedA Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants
Limb-Girdle Muscular Dystrophy, Type 2D
Phase 1 / Phase 22015-02-01
CompletedPhase I/II Study of SRP-4053 in DMD Patients
Duchenne Muscular Dystrophy
Phase 1 / Phase 22015-01-13
CompletedStudy of Eteplirsen in DMD Patients
Duchenne Muscular Dystrophy (DMD)
Phase 32014-11-17
CompletedSafety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
Muscular Dystrophy, Duchenne
Phase 22014-11-01
CompletedA Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
Marburg Hemorrhagic Fever
Phase 12013-05-01
WithdrawnA Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
Ebola Hemorrhagic Fever
Phase 12012-08-01
CompletedEfficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD)
Phase 22012-02-27
CompletedEfficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
Duchenne Muscular Dystrophy
Phase 22011-07-01
TerminatedSafety Study of Single Administration Intravenous Treatment for Influenza
Influenza
Phase 12011-06-01
CompletedSafety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
Marburg Hemorrhagic Fever
Phase 12011-05-01
CompletedSafety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
Ebola Hemorrhagic Fever
Phase 12010-05-01
CompletedDose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) P
Duchenne Muscular Dystrophy
Phase 1 / Phase 22009-01-01
TerminatedSafety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG
Cardiovascular Disease, Coronary Artery Bypass
Phase 22007-03-01
CompletedPharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
West Nile Virus
Phase 12006-10-01
CompletedPharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
Encephalitis
Phase 12006-09-01
CompletedPharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid
Neoplasms
Phase 12006-06-01
TerminatedStudy of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Hepatitis C
Phase 1 / Phase 22005-09-01
CompletedSafety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries
Coronary Artery Disease, Coronary Restenosis
Phase 22005-09-01
TerminatedAn Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease
West Nile Fever
Phase 12004-11-01
TerminatedA Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis
Coronary Artery Disease, Coronary Stent Restenosis
Phase 12003-08-01